🔗 Share this article

Given that the United States continues making historic adjustments to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who initially gained attention by expressing skepticism about coronavirus vaccinations during the global health crisis and has zeroed in on potential deaths following Covid vaccination in her recent position at the FDA.

Scheduled Changes to Pediatric Vaccine Schedule

Agency leaders planned to announce radical changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s immunization schedule, it is understood – a major change that would put the US at odds with a large portion of the international standard with no evidence for public health gain. The announcement has been delayed until the next year.

Instead of Vinay Prasad, Dr. Høeg is listed to present at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to run the division this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon rolling back previously authorized vaccines at the FDA.

The new acting director has often pushed for discontinuing specific pediatric shot schedules in the US so as to align more similar to the Danish model, a society with comprehensive healthcare and a citizenry approximately the population of Wisconsin’s.

To date public appearances, she has continued to focus on vaccines – typically the purview of Prasad, chief of the FDA’s vaccine center – instead of pharmaceutical oversight.

Questions Over Background

Dr. Høeg has no apparent track record in pharmaceutical research, approval processes or management, which has been customary for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, stated Jonathan Howard. “She lacks experience running a scientific study. She is not versed in leading a major agency. She lacks background in pharmaceutical oversight.”

Past directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who ran the center have had.”

This division has an vast workload at the FDA, the former commissioner pointed out.

“The public just pays attention on the novel medication approvals, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and each of these must be managed,” she noted. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant management component to the position, which supervises over 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” Woodcock said.

Response and Disputed Programs

Regarding inquiries about Høeg’s credentials and whether this appointment represents more teamwork among FDA leaders on immunizations, a spokesperson stated that the “questions are based on flawed premises”.

“Her experience aligns with the functions of her job,” the official explained, pointing to the period Dr. Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed one-day drug-approval program that allegedly concerned her preceding directors. “How are these drugs being chosen for this voucher program? Who makes the calls?” Dr. Howard said. “There’s a lot of lack of transparency happening at the regulatory body right now.”

In general, he remarked, “the agency appears to be shifting towards laxer rules of most medications, except for immunizations.”

Public History on Immunizations

Concerning vaccines, Høeg has a more established, if problematic, past, some experts have noted. She released a analysis using non-validated volunteer-provided data to estimate the incidence of myocarditis after Covid immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are more dangerous than they are.

Among her “wish list” for the incoming federal leadership encompassed changing guidelines for novel immunizations and discontinuing “optional” vaccines, she said post-election on a online show. At the agency, Høeg has according to sources floated the idea of barring teenage boys from obtaining Covid vaccines.

“She’s an all-around dogmatist who starts off with her preconceived notions and works backwards to retrofit the science in a extremely misleading, dishonest way,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|